Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe 08:40:10 2024-04-23 am EDT 5-day change 1st Jan Change
90.56 CHF +3.66% Intraday chart for Novartis AG +7.12% +7.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NOVARTIS AG : JP Morgan gives a Neutral rating ZD
NOVARTIS AG : Barclays keeps a Sell rating ZD
Novartis Q1 Core Earnings, Net Sales Rise; 2024 Net Sales Outlook Updated MT
European Midday Briefing: Stocks Buoyed by Strong Earnings, FTSE 100 Hits Fresh Record DJ
North American Morning Briefing : Stock Futures Rise, Tesla Earnings in Focus DJ
NOVARTIS : Oddo BHF confirms its recommendation on the share CF
MORNING BID AMERICAS-Tanking Tesla reports, Europe business beats RE
NOVARTIS AG : UBS remains its Buy rating ZD
Novartis Nominates Former Bristol Myers Squibb CEO as New Chair MT
Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand MT
NOVARTIS AG : Gets a Buy rating from Jefferies ZD
Novartis Raises Guidance on Profit, Sales Growth -- Update DJ
Novartis raises targets for 2024 CF
Techs boost STOXX to one-week high; euro zone data on tap RE
CAC 40: slight upturn in optimism ahead of PMIs CF
Switzerland's Novartis Logs Improved Q1 Net Income, Sales MT
Novartis Raises Guidance on Profit, Sales Growth DJ
EMEA Morning Briefing : Shares Set to Rise as Geopolitical Concerns Ease DJ
Novartis AG Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
US FDA mandates label updates on CAR-T cancer therapies RE
NOVARTIS AG : UBS reiterates its Buy rating ZD
TotalEnergies: shareholders want to separate powers CF
NOVARTIS AG : Deutsche Bank maintains a Buy rating ZD
Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years MT
Novartis: positive efficacy data in MS CF
Chart Novartis AG
More charts
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
95.81 USD
Average target price
105.6 USD
Spread / Average Target
+10.27%
Consensus
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. News Novartis AG
  5. Novartis Said Considering Takeover in Biotech Sector